News from morphotek inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Oct 09, 2013, 09:05 ET

Morphotek, Inc. Announces Initiation Of A New MORAb-004 Phase I Study In Pediatric Patients With Relapsed/Refractory Solid Tumors

 Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that the Children's Oncology Group (COG) has opened enrollment in a Phase 1...

Jul 03, 2013, 09:00 ET

Morphotek Achieves LEED® Certification For New Pilot Plant

Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has achieved LEED® certification for its new 60,000-square-foot...

Jun 25, 2013, 09:30 ET

Morphotek, Inc. Announces Initiation Of A Phase I Study For MORAb-066

 Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that the Sarah Cannon Research Institute in Nashville, Tennessee has opened...

Feb 04, 2013, 09:00 ET

Morphotek Inc. Pilot Plant Receives 2013 Facility of the Year Award

 Morphotek® Inc., a subsidiary of Eisai Inc., announced today that its recently opened 60,000-square-foot pilot plant for the...

Jan 10, 2013, 18:30 ET

Morphotek Announces Top-Line Results of a Phase III Study of Farletuzumab in Patients With Relapsed Platinum-Sensitive Epithelial Ovarian Cancer

 Morphotek® Inc., a wholly-owned subsidiary of Eisai Inc., announced today top-line results from a Phase III study of its investigational...

Nov 12, 2012, 09:00 ET

FDA Grants Orphan Drug Status To Morphotek's Amatuximab (MORAb-009)

 Morphotek® Inc., a subsidiary of Eisai Inc., announced today that the United States Food and Drug Administration (FDA) has granted orphan...

Aug 27, 2012, 09:00 ET

Morphotek®, Inc. Announces Initiation of MORAb-004 Phase II Study in Metastatic Soft Tissue Sarcoma

 Morphotek®, Inc. announced today that it has commenced a multi-center, Phase II study evaluating the safety and efficacy of MORAb-004...

Aug 14, 2012, 14:00 ET
Morphotek, Inc., a wholly-owned subsidiary of Eisai Co., Ltd., commemorates the opening of its newly constructed pilot manufacturing plant in Exton, PA. Pictured left to right are Christopher Molineaux, President, Pennsylvania Bio; Hideki Hayashi, Deputy President and Chief Product Creation Officer, Eisai Co., Ltd.; Nick Nicolaides, President and CEO, Morphotek, Inc.; Haruo Naito, President and CEO, Eisai Co., Ltd.; Philip Sass, Executive Vice President and COO, Morphotek, Inc.; Joye Bramble, Vice President, Pilot Plant Operations, Morphotek, Inc.; Pennsylvania State Senator Andy Dinniman; Eli Avila, Pennsylvania Secretary of Health, and Luigi Grasso, Chief Scientific Officer, Morphotek, Inc.  (PRNewsFoto/Morphotek(R), Inc.)

Morphotek®, Inc. Opens 60,000-square-foot Manufacturing Plant

 Morphotek®, Inc., a wholly-owned subsidiary of Eisai Co., Ltd., today celebrated the grand opening of a new pilot manufacturing plant...

May 30, 2012, 09:00 ET

Morphotek® Earns Prestigious Award For Innovation In Assay Development

 Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that The American Association of Pharmaceutical Scientists (AAPS) has...

Apr 16, 2012, 09:00 ET

Morphotek®, Inc. Announces Initiation of MORAb-004 Phase 2 Study in Metastatic Colorectal Cancer

 Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has commenced a multi-center, Phase II study evaluating the safety...

Mar 27, 2012, 09:00 ET

Morphotek®, Inc. Announces Completion of Enrollment in the FAR-131 Trial for Relapsed Ovarian Cancer

 Morphotek®, Inc., a subsidiary of Eisai Inc., announced today it has completed enrollment of the FAR-131 clinical trial. The study is a...

Jan 10, 2012, 09:00 ET

Morphotek Enters Into Agreements With Fox Chase Cancer Center to Acquire Clinical Samples for the Development and Validation of Companion Diagnostic Kits

 Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has entered into two agreements with Fox Chase Cancer Center ("Fox...

Jun 28, 2011, 09:00 ET

Morphotek®, Inc. Announces Initiation of Farletuzumab Phase II Study in First-Line Treatment of Non-Small Cell Lung Cancer

Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has commenced a multi-center phase II study of farletuzumab in...

Jun 27, 2011, 09:00 ET
Food is loaded onto truck by Morphotek staff.      (PRNewsFoto/Morphotek, Inc.)

Morphotek, Inc. Employees Collect Nearly 9,000 Pounds of Food for Local Families

Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has successfully completed a campaign to collect 8,792 pounds of food...

Jun 08, 2011, 09:00 ET

Morphotek, Inc. Announces That Two Investigational Drugs Have Received Orphan Drug Designations

Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that the United States Food and Drug Administration (FDA) has granted orphan...

Jun 02, 2011, 09:00 ET

Morphotek®, Inc. Announces Initiation of MORAb-004 Phase II Study in Melanoma

Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has commenced a multi-center, phase II study of MORAb-004 for the...

Apr 12, 2011, 09:00 ET

Morphotek Receives Grant to Support Development of Therapeutic Antibodies against Biowarfare Agents

Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that the company has received a grant of approximately $947,000 from the United...

Apr 06, 2011, 09:00 ET

Morphotek®, Inc. Receives Beacon Award From CancerCare

Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it was recently awarded the Beacon Award from CancerCare, a national...

Apr 04, 2011, 21:30 ET

Morphotek®, Inc. Announces Acquisition of Tumor Targeting Assets From Transmolecular, Inc.

Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has acquired certain assets relating to a proprietary tumor targeting...

Mar 29, 2011, 08:00 ET

Morphotek®, Inc. Announces an Agreement with Biocare Medical, LLC to Develop and Commercialize A Diagnostic Kit for Detection of Folate Receptor Alpha in Malignant Tissues

Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has entered into a collaboration and license agreement with Biocare...